Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Medivation Inc    MDVN   US58501N1019

MEDIVATION INC (MDVN)

33
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Medivation Inc : MDVN, OXBT, PTIE and SYMM added to NASDAQ Active Stock Watch List at EPR

10/23/2013 | 10:30am US/Eastern

New York, NY - (ACCESSWIRE) - 10/23/2013 - Equity Profile Report initiates its NASDAQ Gainers Watch List adding Medivation, Inc. (NASDAQ:MDVN), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Pain Therapeutics Inc. (NASDAQ:PTIE), and Symmetricom Inc. (NASDAQ:SYMM)

Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses on development and commercialization of novel therapies to treat serious diseases in the United States is currently up (+8.17%) on 4,286,602 shares traded after Medivation and Astellas Announced the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer. Medivation, Inc. (NASDAQ:MDVN) is currently up (+28.65%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Medivation, Inc. (NASDAQ:MDVN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MDVN&SubId=AW

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+30.00%) on 6,172,456 shares traded after Oxygen Biotherapeutics Signed Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+52.94%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OXBT&SubId=AW

Pain Therapeutics Inc. (NASDAQ:PTIE) a biopharmaceutical company that develops novel drugs is currently up (+16.00%) on 2,154,392 shares traded after Pain Therapeutics Reported that Pfizer Elects to Continue Development of REMOXY. Pain Therapeutics Inc. (NASDAQ:PTIE) is currently up (+75.35%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Pain Therapeutics Inc. (NASDAQ:PTIE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PTIE&SubId=AW

Symmetricom Inc. (NASDAQ:SYMM) a company that provides timekeeping technologies, instruments, and solutions worldwide is currently up (+51.15%) on 16,220,860 shares traded after Symmetricom Reported its First Quarter Fiscal Year 2014 Financial Results. Symmetricom Inc. (NASDAQ:SYMM) is currently up (+66.13%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Symmetricom Inc. (NASDAQ:SYMM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SYMM&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
Latest news on MEDIVATION INC
1d ago MEDIVATION : and Astellas Announce Phase 3 Study of Enzalutamide in Men With Hig..
3d ago MEDIVATION : Announces Participation at Upcoming Investor Conference
10/23 MEDIVATION : Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Anti..
10/23 MEDIVATION : Announces Third Quarter 2014 Financial Results Teleconference on No..
10/22 ASTELLAS PHARMA : Announces Revision of Package Insert in Japan for XTANDI (enza..
10/17 MEDIVATION : Change in Directors or Principal Officers (form 8-K)
10/09 MEDIVATION : EY : Announces leaders from Medivation, MongoDB, Trulia, and zulily..
09/23 MEDIVATION : and Astellas Pharma: FDA Grants Approval for New Xtandi Indication
09/17 ASTELLAS PHARMA : U.S. FDA Approves New Indication for the Use of XTANDI® enzalu..
09/16 MEDIVATION : FDA Grants Approval to New Xtandi Indication
Advertisement
Chart
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF